Matthew J. Barth
Roswell Park Comprehensive Cancer Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Chronic Lymphocytic Leukemia Research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset Chronic Obstructive Pulmonary Disease(2002)177 cited
- → Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice(2014)168 cited
- → Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report(2012)163 cited
- → Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report(2014)130 cited
- → Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R(2017)126 cited
- → Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma(2017)93 cited
- → Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia(2015)90 cited
- → Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice(2017)78 cited
- → Ofatumumab demonstrates activity against rituximab‐sensitive and ‐resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B‐cell lymphoma(2011)72 cited
- → Univariate and multivariate family‐based association analysis of the IL‐13 ARG130GLN polymorphism in the Childhood Asthma Management program(2002)69 cited